ERBB2 and lung adenocarcinoma: However, given the proclivity of mutations to occur in the kinase domains, inhibitors have striking variations in efficacy in clinical trials, particularly in lung cancers, which present with HER2 kinase mutations in 10% of lung adenocarcinomas and HER1 T790M mutations in more than 60% of cases [76, 77].